ReviewBiomedical reports2026
Molecular mechanisms of macrophage migration inhibitory factor in related diseases (Review).
Review in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that exerts dual-faced, context-dependent roles in physiological and pathological processes. While it maintains tissue homeostasis and facilitates repair under normal conditions, MIF acts as a 'double-edged sword' following tissue injury. As a primary initiator of early inflammatory responses, MIF regulates immune cell activation, oxidative stress, and downstream inflammatory cascades. The present review focuses on the molecular mechanisms and therapeutic potential of MIF signaling in three critical inflammation-related conditions: Cerebral infarction, atherosclerosis, and acute kidney injury. It is first delineated how MIF signaling pathways drive disease progression or protection. Furthermore, recent advancements in MIF-targeted therapies are summarized, and the intricate regulatory factors, including dosage, timing, and microenvironmental cues, that govern its bifunctional nature are examined. By highlighting current clinical challenges and prospects, the present review underscores the potential of MIF as a precise therapeutic target for systemic inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.